Roche買 “臨床前”階段 抗體藥物 !! (FDF2 Ab, Galaxy Biotech)

Roche buys rights to preclinical stage oncology program from Galaxy Biotech

Article | 26 September 2012 Switzerland-based Roche (SIX: ROG), the world's largest cancer drug company, has licensed exclusive worldwide development and commercialization rights to privately-held US firm Galaxy Biotech's antibodies targeting fibroblast growth factor 2 (FGF2) for the treatment of cancer for an upfront payment of $8 million. Under the terms of the agreement, Galaxy will also receive milestone payments contingent on various preclinical, clinical, and regulatory development events, as well as royalties on product sales.

Could also develop derivatives Mike Burgess, acting head of Roche pharma research and early development, commented: "Galaxy's humanized monoclonal antibody to FGF2 has demonstrated considerable promise in preclinical studies, and we look forward to developing this and possibly other derivative compounds to complement Roche's already strong portfolio of antibody products in the oncology field."Cary Queen, president of Galaxy Biotech, added: "Roche is one of the world's leading health care companies, with a broad portfolio of innovative products. We are very gratified by their interest in our anti-FGF2 antibodies, and extremely pleased that they will take responsibility for clinical development and commercialization of the program."FGF2 is over-expressed in many types of cancer, and for some tumor types a high level of FGF2 expression correlates with poor clinical outcome. FGF2 has been shown to stimulate not only angiogenesis but also lymphangiogenesis, which may be important in cancer metastasis. Galaxy has developed a novel antibody that neutralizes the biological activity of FGF2, and in published scientific work has shown that the antibody effectively inhibits the growth of certain tumors in animal models.

罗氏提供800万美金资助Galaxy抗体药物研发 发布时间：2012-9-27 来源：药品资讯网信息中心 由高水平科学家组成的Galaxy公司日前获得了来自罗氏集团800万美元的投资，罗氏公司希望获得其抗癌抗体药物的授权。报告同时指出，罗氏仍在计划支付药物的特权使用费并提供额外的里程碑资金。这一投资针对纤维细胞生长因子(FGF2)抗体，这一蛋白与肿瘤的转移密切相关。罗氏公司表示FGF2抗体动物实验数据给公司留下了深刻的印象，表明抗体大有可能有效抑制肿瘤生长。罗氏公司药物早起研发部门负责人Mike Burgess表示，Galaxy开发的这一抗体在临床研究之前就已经表现出巨大的潜力。公司希望以之为基础开发新的衍生物，用于补充罗氏公司已经很强大的癌症抗体药物生产线。Galaxy已经运营十年之久，由Protein Design Labs的共同创始人Cary Queen、前基因泰克科学家Jin Kim、富于新药研发经验的James Larrick共同创立。Geller生物制药全权代理这一协议。